Senior Director, HEOR and Pricing

Overview

Create a future where DNA is no longer destiny. Join Rocket Pharma.

Rocket Pharma is a fully integrated, late-stage biotechnology company advancing gene therapies with curative potential for patients with rare and life-threatening diseases. We are a team of creative, compassionate, and driven individuals united by a profound mission of seeking gene therapy cures. Rocket places tremendous value on our people and fosters a collaborative environment where bold ideas thrive and every team member makes a meaningful impact.

Our core values guide everything we do: we trust one another, show generosity toward patients, embrace curiosity, and strive to elevate science. Team members receive a competitive total rewards package, including equity participation, 401(k) matching, and excellent health benefits.

The Senior Director, Health Economics and Outcomes Research (HEOR) & Pricing will lead Rocket’s integrated pricing, value and evidence framework to support the clinical, economic, societal and access value of Rocket's gene therapy portfolio, with a primary focus on rare genetic cardiomyopathies and one-time in‑vivo AAV gene therapies.

This leader will play a pivotal role in shaping payer evidence generation and will oversee global pharmacoeconomic models, evidence synthesis, disease registries, observational and retrospective research, external HEOR partnerships, and data‑gap identification needed to support a compelling health‑economic value proposition. This role will also be responsible for pricing strategies and access architecture to optimize product value across health systems. The role will ensure evidence plans reflect payer expectations, HTA requirements, regional reimbursement dynamics and patient access considerations facing gene therapies in global markets.

Integrated value, evidence and economic strategy

• Lead development of integrated economic narrative and value communication platforms that articulate the clinical, economic, societal and health‑system value of Rocket therapies for payers, HTA agencies, providers and health systems.
• Build a clear health‑economic and access value proposition for Rocket's genetic cardiomyopathy portfolio
• Develop and execute global HEOR strategy and tactics aligned with product strategy and market access priorities, to support optimal access, reimbursement and value recognition for Rocket gene therapies.
• Serve as a strategic bridge across U.S. and ex-U.S. stakeholders to ensure evidence plans reflect evolving payer insights, HTA requirements, regional access considerations and launch sequencing priorities while maintaining a consistent global value framework.

Pricing strategy and access architecture

• Define global pricing architecture and strategy for one‑time gene therapies, incorporating launch sequencing, HTA value thresholds, international reference pricing, country access archetypes, market‑specific reimbursement pathways, evidence threshold assessment
• Outline novel approaches to shape sustainable access and value recognition for one‑time gene therapies. Design and conduct payer and pricing research, advisory boards and value message testing.
• Monitor U.S. and ex‑U.S. policy, payer, HTA and reimbursement dynamics that may influence patient access, price realization, affordability, uptake and reimbursement for Rocket's gene therapy portfolio.

Evidence generation, RWE and economic modeling

• Build and execute health economic strategy to support access value proposition, including burden of illness studies, cost‑effectiveness models, budget impact models, and scenario analyses that demonstrate value to patients, payers, health systems and society.
• Design and implement real‑world evidence programs to strengthen the target product profile, address payer evidence needs and support market access across geographies, including systematic literature reviews, evidence synthesis, natural history and real‑world data analyses, registry strategies, and post‑launch evidence plans.
• Conduct economic evaluations as the basis for payer assessments, HTA submissions, disease management guidelines and formulary evaluations.
• Translate HEOR evidence into…